The use of drug checking legislation to facilitate illicit drug consumption research: psychedelic microdosing as a case example

Purpose Current laws prohibiting access to illicit drugs contribute to drug harms as manufacturers and distributors of illicit substances have variable influence over drug supply and quality. Legislation introduced in New Zealand (NZ) in 2021 aimed to address such harm by enabling licenced drug checking providers to directly analyse samples from consumers. This paper aims to detail the use of drug checking legislation for research purposes, and the licence aquisition process for the first licence of this kind. Design/methodology/approach Samples purported to be psychedelic drugs were analysed using this licence in the context of “microdosing”. Analysis of illicitly sourced substances used by people who microdose (PWM) addresses a gap in the literature; no research to date has collected and analysed samples to determine the extent to which drug content differs from consumer expectations. Obtaining a drug checking licence was required to legally collect microdose samples from participants. Findings Acquisition of the licence was a lengthy process. It is hoped that successful legislation in this instance will pave the way forward for future research using drug checking. The approval of the licence allowed participants to provide samples of illicitly sourced microdosing substances for analysis. Drug checking legislation enabled drug use research involving PWM and facilitated the provision of harm reduction information for this population. Originality/value This study demonstrates the usefulness of drug checking legislation in research as a means to inform policy, improve safety and support evidence-based best practice for both researchers and people who use drugs.